Prognostic and predictive factors in pancreatic cancer

Emanuela Dell’Aquila, Claudia Angela Maria Fulgenzi, Alessandro Minelli, Fabrizio Citarella _, Marco Stellato, Francesco Pantano, Marco Russano, Maria Concetta Cursano, Andrea Napolitano, Tea Zeppola, Bruno Vincenzi, Giuseppe Tonini and Daniele Santini

PDF  |  Full Text  |  How to cite  |  Press Release  |  Order a Reprint

Oncotarget. 2020; 11:924-941. https://doi.org/10.18632/oncotarget.27518

Metrics: PDF 1091 views  |   Full Text 2112 views  |   ?  


Emanuela Dell’Aquila1, Claudia Angela Maria Fulgenzi1, Alessandro Minelli1, Fabrizio Citarella1, Marco Stellato1, Francesco Pantano1, Marco Russano1, Maria Concetta Cursano1, Andrea Napolitano1, Tea Zeppola1, Bruno Vincenzi1, Giuseppe Tonini1 and Daniele Santini1

1 Department of Medical Oncology, University Campus Bio-Medico, Rome 00128, Italy

Correspondence to:

Fabrizio Citarella,email: f.citarella@unicampus.it

Keywords: metastatic pancreatic cancer; predictive and prognostic factors; CA19-9; gemcitabine-abraxane; FOLFIRINOX

Received: January 19, 2020     Accepted: February 17, 2020     Published: March 10, 2020


Pancreatic cancer is one of the leading causes of cancer death worldwide. Its high mortality rate has remained unchanged for years. Radiotherapy and surgery are considered standard treatments in early and locally advanced stages. Chemotherapy is the only option for metastatic patients. Two treatment regimens, i. e. the association of 5-fluorouracil- irinotecan-oxaliplatin (FOLFIRINOX) and the association of nab-paclitaxel with gemcitabine, have been shown to improve outcomes for metastatic pancreatic adenocarcinoma patients. However, there are not standardized predictive biomarkers able to identify patients who benefit most from treatments. CA19-9 is the most studied prognostic biomarker, its predictive role remains unclear. Other clinical, histological and molecular biomarkers are emerging in prognostic and predictive settings. The aim of this review is to provide an overview of prognostic and predictive markers used in clinical practice and to explore the most promising fields of research in terms of treatment selection and tailored therapy in pancreatic cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 27518